Company Profile

Endologix, Inc. develops, manufactures, markets and sells medical devices for the treatment of aortic disorders. The Company's products are designed for the minimally-invasive endovascular treatment of abdominal aortic aneurysms (AAA). Its AAA products are developed on one of two platforms: traditional minimally-invasive endovascular aneurysm repair (EVAR) or endovascular aneurysm sealing (EVAS), the Company's solution for sealing the aneurysm sac while maintaining blood flow. The Company's EVAR products include the AFX Endovascular AAA System (AFX System), the VELA Proximal Endograft (VELA) and the Ovation Abdominal Stent Graft System (Ovation System). The Company's EVAS product is the Nellix Endovascular Aneurysm Sealing System (the Nellix EVAS System).

Employees

Sector

Medical Equipment, Supplies & Distribution

More about the company

19/05	Endologix LLC acquired Pounce? Thrombectomy System from Surmodics, Inc.	CI
07/05	Endologix LLC Announces Appointment of Steve Deitsch to Board of Directors	CI
09/25/09	Endologix Announces That Scott Huennekens Joins Board of Directors	CI
20/25/20	Endologix Announces 1000 Patients Treated with the Detour? System	CI
03/25/03	Endologix LLC Appoints Andrew Davis as Chief Commercial Officer	CI
07/25/07	Endologix LLC Announces Chief Executive Officer Changes	CI
07/25/07	Endologix LLC Announces Executive Changes	CI
06/24/06	Endologix LLC Announces 36-Month Results of Detour2 Study At 2024 Viva Late-Breaking Clinical Trial Session	CI
18/24/18	Endologix LLC Appoints Graham Phillips as Chief Operating Officer	CI
13/24/13	Endologix LLC Announces Online Publication of the One-Year Results of the DETOUR2 Trial in the Journal of Vascular Surgery	CI
05/24/05	Endologix LLC Appoints Mike Mathias as Chief Commercial Officer	CI
25/24/25	Endologix LLC Announces That Art Taylor Joins Board of Directors	CI
09/24/09	Endologix LLC Appoints Scott Ward Joins Board of Directors	CI

01/20/01	ENDOLOGIX INC /DE/ : Other Events (form 8-K)	AQ
10/20/10	ENDOLOGIX : DE/ MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-Q)	AQ
13/20/13	Endologix : Ninth Circuit Addresses High Standard For Pleading Scienter Under Private Securities Litigation Reform Act	AQ
10/20/10	ENDOLOGIX INC /DE/ : Entry into a Material Definitive Agreement, Bankruptcy or Receivership, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Triggering Events That Accelerate or Increase a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits (form 8-K)	AQ
06/20/06	ENDOLOGIX INC /DE/ : Other Events, Financial Statements and Exhibits (form 8-K)	AQ

Manager	Title	Age	Since
John Liddicoat CEO	Chief Executive Officer	62	07/01/2025
Cindy Pinto DFI	Director of Finance/CFO	-	01/09/2014
Graham Phillips COO	Chief Operating Officer	-	18/06/2024

Director	Title	Age	Since
Sumner Esten Anderson BRD	Director/Board Member	-	-
Andrew ElBardissi BRD	Director/Board Member	44	01/11/2020
Avi Kometz BRD	Director/Board Member	-	-

Date	Insider	Type	Main position	Quantity	% Market Cap.
04/20/04	Daniel Lemaitre	Sell	Director	51,844	0.2510%
13/20/13	Daniel Lemaitre	Sell	Director	2,253	0.0109%
12/20/12	Gregory Waller	Sell	Director	28,630	0.1386%

Endologix, Inc. Share Price

Stocks

ELGXQ

US29266S3040

Medical Equipment, Supplies & Distribution

Latest news : Endologix, Inc.

Press Releases: Endologix, Inc.

Quotes and Performance

Managers and Directors: Endologix, Inc.

Latest insider transactions

Medical Devices & Implants

Company Profile

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ENDOLOGIX, INC.	-24.28%	-33.67%	-	-	4L
STRYKER CORPORATION	+2.15%	+2.14%	-17.25%	+10.81%	12TCr
SMITH & NEPHEW PLC	-0.31%	-1.22%	+3.56%	-4.71%	1.29TCr
GLAUKOS CORPORATION	+2.05%	+1.45%	+29.93%	+90.52%	744.45Cr
IMEIK TECHNOLOGY DEVELOPMENT CO.,LTD.	+1.87%	-4.66%	-46.88%	-69.45%	419.91Cr
DOUBLE MEDICAL TECHNOLOGY INC.	+2.06%	+4.10%	+11.98%	+37.03%	254.61Cr
BEIJING BALANCE MEDICAL TECHNOLOGY CO.,LTD.	+5.46%	+10.04%	-15.76%	-14.08%	179.62Cr
SHANGHAI MICROPORT ENDOVASCULAR MEDTECH CO., LTD.	+1.67%	-5.73%	+5.08%	-9.77%	165.98Cr
L&C BIO CO.,LTD	-8.89%	-10.79%	+152.96%	+119.71%	136.83Cr
Average	-2.02%	+0.88%	+15.45%	+20.01%	1.9TCr
Weighted average by Cap.	+1.86%	+1.76%	-11.70%	+12.08%